Gambro Prismaflex TPE 2000 Set
Vantive US Healthcare, LLC · Decision date Dec 23, 2025
What did the FDA decide?
FDA records P830063/S031 as a supplement to PMA P830063, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 23, 2025.
FDA approval order statement
a new mold for the soft extension pierceable component of the Prismaflex TPE 2000 set
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Dec 23, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P830063/S031
- Regulatory pathway
- PMA supplement
- Applicant
- Vantive US Healthcare, LLC
- Product code
- MDP
- Decision code
- OK30
- Decision date
- Dec 23, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Separator for therapeutic purposes, membrane automated blood cell/plasma.
- Applicant
- Vantive US Healthcare, LLC
- Product code
- MDP
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P830063/S031 received
Application receipt date recorded by FDA.
P830063/S031 · FDA decision
30-Day Notice
P830063/S030 · Related supplement
Prismaflex TPE2000 Set
P830063/S032 · Related supplement
PRISMAFLEX TPE2000 SET
Timeline entries are records held by MedtechLedger for P830063. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P830063
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Prismaflex TPE2000 SetP830063/S030 | Vantive US Healthcare, LLC | PMA supplement | Mar 13, 2026 | FDA |
PRISMAFLEX TPE2000 SETP830063/S032 | Vantive US Healthcare, LLC | PMA supplement | Jul 15, 2026 | FDA |
Explore the linked device profile
Other records with product code MDP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Plasmaflo OP-05 W(A)P820033/S019 | Asahi Kasei Medical Co., Ltd. | PMA supplement | Apr 9, 2026 | FDA |
Plasmaflo OP-05W(A)P820033/S017 | Asahi Kasei Medical Co., Ltd. | PMA supplement | Sep 30, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Vantive US Healthcare, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 510 Lake Cook Rd., Deerfield, IL, 60015
Sources and methodology
- Original FDA record: P830063/S031
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


